Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. - Dataset (ID:20270)

Small Molecules Studied

HMS LINCS ID Name Alternative Names LINCS ID Structure Image PubChem CID
10008-3 Sorafenib
BAY-439006
LSM-1008 216239
10175-3 Sunitinib
Sutent; SU11248
LSM-42800 3086686
10102-3 Taxol
Paclitaxel
LSM-1102 441276
10276-1 TCS 2312 LSM-6362 11258443
10520-1 TCS PIM-1 1 1235170
10277-1 Temsirolimus LSM-4295 148191
10278-1 Topotecan
Hycamtin
LSM-5662 60700
10345-3 Torkinib
PP242
LSM-6357 57347681
10021-5 Tozasertib
VX680; MK-0457
LSM-1021 5494449
10136-2 TPCA-1 LSM-1136 9903786
10142-2 Trametinib
GSK-1120212; GSK1120212; GSK1120212B; JTP-74057
LSM-1143 11707110
10279-1 Trichostatin A LSM-43005
10280-1 Triciribine LSM-3810 65399
10346-1 Valproic acid
Depakine
LSM-4620 3549980
10281-1 Vinorelbine
Navelbine
LSM-6302 5311497
10282-1 Vorinostat
suberoylanilide hydroxamic acid (SAHA); Zolinza
LSM-3828 5311
10283-1 XRP44X
AG-G-87906
LSM-4298 10339779
10275-1 (Z)-4-Hydroxytamoxifen LSM-43294 53770298
10348-1 Z-Leu-Leu-Norvalinal
MG-115
LSM-6358 9868928
10096-2 ZM-447439 LSM-1096 9914412